Previous 10 | Next 10 |
Exagen Inc. (XGN) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Paul Knig...
The following slide deck was published by Exagen Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Exagen Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Exagen Inc. (NASDAQ: XGN) Q3 2021 Earnings Call Nov 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Exagen Inc. (XGN) Q3 2021 Earnings Call Transcript
Exagen (NASDAQ:XGN): Q3 GAAP EPS of -$0.42 beats by $0.02. Revenue of $12.25M (+13.6% Y/Y) beats by $0.12M. For the full year 2021, Exagen reaffirms its prior guidance and expects revenue to be in the range of $47-$49M vs. consensus of $47.97M Press Release For further details see: ...
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021. Third Quarter Highlights: Generated total revenue of $12.3 million...
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum, which takes place November 18 ...
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. Ron Rocca, Exagen’s Pr...
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered service with Inland Empire Health Plan (IEHP), providing enhanced care to over ...
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that it entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital Partners, LLC...
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the American College of Rheumatology’s (ACR) virtual annual meeting, ACR Convergence ...
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...